27 February 2012 <\/p>\n
Angel Biotechnology Holdings plc <\/p>\n
(\"Angel\" or \"the Company\") <\/p>\n
Grant of Share Options - Enterprise Management Incentive (EMI) Scheme <\/p>\n
Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce share options totaling 16,806,723 were awarded to Dr. Stewart White, Commercial Director, under the Company's Enterprise Management Incentive (EMI) share option scheme on 24 February 2012. All share options are exercisable at a price of 0.238p per share, subject to performance and retention criteria being met and are the first share options awarded to Dr. White since his appointment last year. <\/p>\n
The exercise dates are as follows: <\/p>\n
Exercise Dates <\/p>\n
Number of options <\/p>\n
04\/06\/2012 - 03\/06\/2022 <\/p>\n
3,361,345 <\/p>\n
31\/12\/2012 - 30\/12\/2022 <\/p>\n
6,722,689 <\/p>\n
31\/03\/2013 - 30\/03\/2023 <\/p>\n
6,722,689 <\/p>\n
Dr Paul Harper, Executive Chairman of Angel Biotechnology Holdings plc said: <\/p>\n
\"The Board of Directors is delighted to award these options to Dr. White to reflect the commitment made to ensure the success of the Company.\" <\/p>\n
For further information: <\/p>\n
Angel Biotechnology Holdings plc <\/p>\n
Lorna Peers, Finance Director +44 (0) 131 445 6077 <\/p>\n
Stewart White, Commercial Director http:\/\/www.angelbio.com<\/a> <\/p>\n Grant Thornton, Corporate Finance <\/p>\n Colin Aaronson \/ Melanie Frean \/ Elliot Berg +44 (0) 20 7383 5100 <\/p>\n Hybridan LLP (Broker) <\/p>\n Claire Noyce \/ Deepak Reddy +44 (0) 20 7947 4350 <\/p>\n Media (Frankfurt: 725292 - news) enquiries: <\/p>\n The Communications Portfolio Ltd <\/p>\n Ariane Comstive \/ Caolan Mahon +44 (0) 20 7536 2028 \/ 2029 <\/p>\n ariane.comstive@communications-portfolio.co.uk<\/a> <\/p>\n Notes to Editors: <\/p>\n Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis. <\/p>\n Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA). <\/p>\n Its (Euronext: ALITS.NX - news) customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings. <\/p>\n Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 - news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people. <\/p>\n More information is available at http:\/\/www.angelbio.com<\/a> . <\/p>\n - Ends - <\/p>\n<\/p>\n See the original post here: 27 February 2012 Angel Biotechnology Holdings plc (\"Angel\" or \"the Company\") Grant of Share Options - Enterprise Management Incentive (EMI) Scheme Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce share options totaling 16,806,723 were awarded to Dr. Continue reading
\nAngel Biotechnology - Grant of Share Options<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"